Sanford opens I-SPY 2 clinical trial for breast cancer

Shawn Neisteadt
Sanford Health Media Relations
605-366-2432 /

SIOUX FALLS, S.D., Feb. 4, 2021 — Sanford Health has a new option for patients diagnosed with breast cancer. The I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And molecular anaLysis 2), is an adaptive platform clinical trial, created to identify successful treatments for Stage II/III breast cancer while minimizing the number of required participants and time required to evaluate the treatments. In essence, it is the most efficient clinical trial platform available.

I-SPY 2 is a novel treatment study for locally advanced breast cancer. It is now available at Sanford USD Medical Center in Sioux Falls, and 20 leading cancer centers across the United States. The collaboration allows potential treatments and drugs to be evaluated in a fashion that is faster than traditional studies, and aims to offer access to trial participation to a greater number of patients.

Building upon the original I-SPY 1 clinical trial. I-SPY 2 has screened over 3000 patients and has graduated several promising investigational treatments.

Sanford Health patients who may be interested in enrolling in I-SPY 2, or other clinical trials, should talk with their providers about their options.

About Sanford Health

Sanford Health, one of the largest health systems in the United States, is dedicated to the integrated delivery of health care, genomic medicine, senior care and services, global clinics, research and affordable insurance. Headquartered in Sioux Falls, South Dakota, the organization includes 44 hospitals, 1,400 physicians and more than 200 Good Samaritan Society senior care locations in 26 states and nine countries. Learn more about Sanford Health’s transformative work to improve the human condition at or Sanford Health News.